🎉 M&A multiples are live!
Check it out!

OnKure Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for OnKure Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Benevolent AI.

OnKure Therapeutics Overview

About OnKure Therapeutics

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.


Founded

2011

HQ

United States of America
Employees

46

Financials

LTM Revenue $0.2M

LTM EBITDA n/a

EV

-$68.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

OnKure Therapeutics Financials

OnKure Therapeutics has a last 12-month revenue of $0.2M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, OnKure Therapeutics achieved revenue of n/a and an EBITDA of -$51.7M.

OnKure Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See OnKure Therapeutics valuation multiples based on analyst estimates

OnKure Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$36.4M -$51.7M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$29.5M -$35.3M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

OnKure Therapeutics Stock Performance

As of April 15, 2025, OnKure Therapeutics's stock price is $3.

OnKure Therapeutics has current market cap of $40.8M, and EV of -$68.8M.

See OnKure Therapeutics trading valuation data

OnKure Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$68.8M $40.8M XXX XXX XXX XXX $-12.37

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

OnKure Therapeutics Valuation Multiples

As of April 15, 2025, OnKure Therapeutics has market cap of $40.8M and EV of -$68.8M.

OnKure Therapeutics's trades at -358.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate OnKure Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for OnKure Therapeutics and 10K+ public comps

OnKure Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$68.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.3x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get OnKure Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

OnKure Therapeutics Valuation Multiples

OnKure Therapeutics's NTM/LTM revenue growth is 248%

OnKure Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.

Over next 12 months, OnKure Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate OnKure Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for OnKure Therapeutics and other 10K+ public comps

OnKure Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 42% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

OnKure Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

OnKure Therapeutics M&A and Investment Activity

OnKure Therapeutics acquired  XXX companies to date.

Last acquisition by OnKure Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . OnKure Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by OnKure Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About OnKure Therapeutics

When was OnKure Therapeutics founded? OnKure Therapeutics was founded in 2011.
Where is OnKure Therapeutics headquartered? OnKure Therapeutics is headquartered in United States of America.
How many employees does OnKure Therapeutics have? As of today, OnKure Therapeutics has 46 employees.
Who is the CEO of OnKure Therapeutics? OnKure Therapeutics's CEO is Dr. Nicholas A. Saccomano, PhD.
Is OnKure Therapeutics publicy listed? Yes, OnKure Therapeutics is a public company listed on NAS.
What is the stock symbol of OnKure Therapeutics? OnKure Therapeutics trades under OKUR ticker.
When did OnKure Therapeutics go public? OnKure Therapeutics went public in 2024.
Who are competitors of OnKure Therapeutics? Similar companies to OnKure Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of OnKure Therapeutics? OnKure Therapeutics's current market cap is $40.8M
What is the current revenue of OnKure Therapeutics? OnKure Therapeutics's last 12-month revenue is $0.2M.
What is the current EV/Revenue multiple of OnKure Therapeutics? Current revenue multiple of OnKure Therapeutics is -358.9x.
Is OnKure Therapeutics profitable? Yes, OnKure Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.